AR097038A1 - Uso de un ligando de cd6 y método basado en el - Google Patents

Uso de un ligando de cd6 y método basado en el

Info

Publication number
AR097038A1
AR097038A1 ARP140102744A ARP140102744A AR097038A1 AR 097038 A1 AR097038 A1 AR 097038A1 AR P140102744 A ARP140102744 A AR P140102744A AR P140102744 A ARP140102744 A AR P140102744A AR 097038 A1 AR097038 A1 AR 097038A1
Authority
AR
Argentina
Prior art keywords
methods
lymphocytes
auxiliary
cells
treatment
Prior art date
Application number
ARP140102744A
Other languages
English (en)
Inventor
Enrique Montero Casimiro Jose
Bughani Usha
Barve Abhijit
Nair Pradip
Melarkode Ramakrishnan
S Manian Bala
Original Assignee
Centro De Inmunología Molecular
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Inmunología Molecular, Biocon Ltd filed Critical Centro De Inmunología Molecular
Publication of AR097038A1 publication Critical patent/AR097038A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)

Abstract

La presente trata sobre los métodos para el tratamiento y la prevención de condiciones mediadas por linfocitos T (células T), T-auxiliar 17 (Thl7) y/o T-auxiliar 1 (Th1). En particular, la presente trata sobre el uso de anticuerpos anti CD6 para el tratamiento de condiciones mediadas por linfocitos T autorreactivos Th17 y Th1. Los métodos de la presente tienen posterior utilidad en métodos para modular una respuesta inmune mediante la supresión de la producción de citoquina IL-23R, disminuyendo por lo tanto la inflamación mediada por las células Th17. Reivindicación 6: El compañero de unión que se une específicamente a CD6 para su uso según la reivindicación 4, en donde el anticuerpo humanizado es Itolizumab.
ARP140102744A 2013-07-23 2014-07-24 Uso de un ligando de cd6 y método basado en el AR097038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3264CH2013 2013-07-23

Publications (1)

Publication Number Publication Date
AR097038A1 true AR097038A1 (es) 2016-02-17

Family

ID=52392806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102744A AR097038A1 (es) 2013-07-23 2014-07-24 Uso de un ligando de cd6 y método basado en el

Country Status (15)

Country Link
US (3) US10189899B2 (es)
EP (3) EP3024485B1 (es)
JP (4) JP6530391B2 (es)
KR (3) KR102276745B1 (es)
AR (1) AR097038A1 (es)
AU (3) AU2014294616B2 (es)
CA (1) CA2920368C (es)
DK (1) DK3024485T3 (es)
ES (1) ES2843683T3 (es)
HK (1) HK1225298A1 (es)
NZ (1) NZ746944A (es)
PL (1) PL3024485T3 (es)
PT (1) PT3024485T (es)
TW (1) TW201511772A (es)
WO (1) WO2015011658A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524233B2 (en) 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof
DK3024485T3 (da) 2013-07-23 2020-12-07 Biocon Ltd Anvendelse af en CD6-bindingspartner og fremgangsmåde baseret derpå
IL266087B2 (en) * 2016-10-18 2024-02-01 Biocon Ltd Use of itolizumab to reduce CD6 phosphorylation
DK3529274T3 (da) 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
US20210395329A1 (en) * 2018-06-29 2021-12-23 City Of Hope Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
US20230364233A1 (en) * 2020-09-28 2023-11-16 Vor Biopharma Inc. Compositions and methods for cd6 modification

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
JPH09508784A (ja) 1993-11-02 1997-09-09 デューク ユニヴァーシティー Ｃｄ６リガンド
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
SK282894B6 (sk) 1996-03-20 2003-01-09 Hoechst Marion Roussel Tricyklické zlúčeniny, spôsob ich prípravy a medziprodukty tohto spôsobu, ich použitie ako liečiv a farmaceutické zmesi, ktoré ich obsahujú
JP2001523956A (ja) 1997-03-03 2001-11-27 ブリストル−マイヤーズ・スクイブ・カンパニー ヒトｃｄ６に対するモノクローナル抗体
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
EP1637160A3 (en) 1999-05-07 2006-05-03 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2402596A1 (en) 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
EP1283721A4 (en) 2000-05-26 2004-07-07 Smithkline Beecham Corp ANTI-RANK-LIGAND-BINDING MONOCLONAL ANTIBODIES USEFUL FOR TREATING DISEASES CAUSED BY THE RANK-LIGANDS
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2003265361A1 (en) 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
CA2555820C (en) 2004-02-19 2016-01-19 Genentech, Inc. Cdr-repaired antibodies
MXPA06014075A (es) * 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
KR101027427B1 (ko) 2004-11-12 2011-04-11 젠코어 인코포레이티드 ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체
CA2595380A1 (en) 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
BRPI0713421A2 (pt) 2006-06-14 2012-03-13 Imclone Systems Incorporated Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
CN105251004A (zh) 2006-12-26 2016-01-20 分子免疫中心 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
RU2454245C2 (ru) 2006-12-26 2012-06-27 Сентро Де Инмунология Молекулар Фармацевтические композиции, способные вызывать апоптоз опухолевых клеток, для диагностики и лечения в-клеточной хронической лимфоцитарной лейкемии
US20090060906A1 (en) 2007-01-09 2009-03-05 Wyeth Anti-IL-13 antibody formulations and uses thereof
JP2010111581A (ja) * 2007-01-25 2010-05-20 Imuno:Kk ドーパミンｄ２様受容体アゴニストを有効成分とする医薬及びスクリーニング方法
US8119133B2 (en) * 2007-02-28 2012-02-21 Schering Corporation Engineered anti-IL-23R antibodies
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
WO2009092087A2 (en) * 2008-01-18 2009-07-23 The Brigham And Women's Hospital, Inc. Selective differentiation, identification, and modulation of human th17 cells
US8524233B2 (en) 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof
PT3721904T (pt) 2009-11-20 2021-11-15 Biocon Ltd Formulações de anticorpo t1h
GB201013975D0 (en) * 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
US9216988B2 (en) * 2011-12-22 2015-12-22 Genentech, Inc. Benzyl sulfonamide derivatives as RORc modulators
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
DK3024485T3 (da) 2013-07-23 2020-12-07 Biocon Ltd Anvendelse af en CD6-bindingspartner og fremgangsmåde baseret derpå
IL266087B2 (en) 2016-10-18 2024-02-01 Biocon Ltd Use of itolizumab to reduce CD6 phosphorylation
DK3529274T3 (da) 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
JP2021515039A (ja) 2018-02-27 2021-06-17 エクイリウム, インコーポレイテッドEquillium, Inc. 重症喘息を処置するための組成物および方法

Also Published As

Publication number Publication date
KR102276745B1 (ko) 2021-07-14
EP3936148A1 (en) 2022-01-12
EP3024485A4 (en) 2017-03-08
AU2014294616A1 (en) 2016-02-18
US11028168B2 (en) 2021-06-08
ES2843683T3 (es) 2021-07-20
CA2920368A1 (en) 2015-01-29
AU2021240292A1 (en) 2021-10-28
AU2014294616B2 (en) 2019-07-11
US10189899B2 (en) 2019-01-29
HK1225298A1 (zh) 2017-09-08
AU2019246781A1 (en) 2019-10-31
DK3024485T3 (da) 2020-12-07
EP3024485A1 (en) 2016-06-01
JP7221264B2 (ja) 2023-02-13
KR20190120426A (ko) 2019-10-23
PL3024485T3 (pl) 2021-06-14
WO2015011658A1 (en) 2015-01-29
US20160152705A1 (en) 2016-06-02
KR20160033786A (ko) 2016-03-28
US20190345247A1 (en) 2019-11-14
JP6868655B2 (ja) 2021-05-12
US20220025038A1 (en) 2022-01-27
NZ716381A (en) 2021-06-25
PT3024485T (pt) 2021-01-25
NZ746944A (en) 2021-07-30
CA2920368C (en) 2023-03-21
EP3024485B1 (en) 2020-11-18
AU2019246781B2 (en) 2021-07-01
TW201511772A (zh) 2015-04-01
JP2019112446A (ja) 2019-07-11
JP2016525538A (ja) 2016-08-25
JP6530391B2 (ja) 2019-06-12
KR20210088739A (ko) 2021-07-14
JP2021038266A (ja) 2021-03-11
KR102034757B1 (ko) 2019-10-21
KR102405247B1 (ko) 2022-06-07
JP2022145689A (ja) 2022-10-04
EP3738613A1 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
ECSP18043564A (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
AR097038A1 (es) Uso de un ligando de cd6 y método basado en el
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
CO2019013935A2 (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
BR112017026330A2 (pt) molécula de ligação de lag-3 capaz de ligação tanto o lag-3 humano quanto ao lag-3 de macaco cynomolgus
CO7400878A2 (es) Anticuerpos anti-mcam y métodos de uso asociados
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
BR112017003582A2 (pt) anticorpos, composições e usos
CU24498B1 (es) Anticuerpos de factor xi
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CL2015000352A1 (es) Métodos de tratamiento de una tauopatía
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
MX2016006316A (es) Inhibidores de mtor para potenciar la respuesta inmunitaria.
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
AR090585A1 (es) Anticuerpos anti-hla-b*27 y usos de estos
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure